异动解读|阿尔尼拉姆制药公司盘前下跌5.34%,三季度营收虽超预期但市场情绪偏谨慎

行情直击
Oct 29

10月29日,阿尔尼拉姆制药公司盘前下跌5.34%,报223.9美元/股,成交额62.05万美元。

消息面上,公司披露三季度调整后每股收益16.26美元,销售额14.58亿美元,高于市场预期的14.34亿美元。但公司此前在7月底曾因下调全年净产品收入指引至47亿至51亿美元引发股价大跌,市场对后续增长持续性仍较敏感。

此外,公司近期公布brezosiran一期数据,最高剂量组3个月脑脊液突变亨廷顿蛋白平均降幅达60%至64%,并计划推进关键研究,显示管线仍有进展支撑。

阿尔尼拉姆制药公司是一家专注于RNAi疗法研发的生物制药公司,致力于通过基因沉默机制开发针对多种疾病的新型治疗方案。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10